GlassScriptPhysician profile
Sindhu Subramanian
NPI 1023570330
$8,249.97
in general payments reported to CMS, 2019-2025
29 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $2,147 · 2021: $454 · 2022: $967 · 2023: $3,159 · 2024: $639 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371 · Travel and Lodging: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.47 |
| Travel and Lodging | $2,051.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,367.61 | 2022-2025 | Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps, Alloderm |
| Intuitive Surgical, INC. | $1,580.17 | 2020 | |
| Tela Bio, INC. | $533.30 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Astrazeneca Pharmaceuticals LP | $324.12 | 2023-2024 | Andexxa |
| Kci USA, INC. | $321.04 | 2020-2023 | V.A.C. Veraflo, Prevena, Fistula Solution |
| Medical Device Business Services, INC. | $305.00 | 2020 | |
| Csl Behring | $292.40 | 2019-2021 | |
| Ethicon US, LLC | $176.85 | 2020-2022 | |
| Avita Medical Americas, LLC | $164.52 | 2024 | |
| Stryker Corporation | $157.58 | 2020-2023 | Spy-Phi System |
| Allergan, INC. | $152.64 | 2021-2022 | |
| Davol INC. | $148.07 | 2023 | Arista Ah Flexitip |
| Integra Lifesciences Corporation | $95.47 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Pacira Pharmaceuticals Incorporated | $90.05 | 2020-2022 | |
| Pfizer INC. | $80.39 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $60.81 | 2019 | |
| Kerecis Limited | $50.87 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Janssen Pharmaceuticals, INC | $49.71 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.17 | 2019-2023 | Camzyos |
| Smith+Nephew, INC. | $40.60 | 2024 | Grafix Pl, Stravix |
| Lemaitre Vascular, INC. | $40.25 | 2023 | Xenosure Biologic Patch |
| Medtronic, INC. | $36.86 | 2023 | Signia |
| Becton, Dickinson and Company | $24.54 | 2021 | |
| Avanos Medical | $21.43 | 2022 | |
| Teleflex LLC | $21.25 | 2023 | Quikclot |
| Urgo Medical North America, LLC | $19.40 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Urgok2 |
| Merck Sharp & Dohme LLC | $17.97 | 2021 | |
| Boston Scientific Corporation | $15.22 | 2023 | Spyglass |
| W. L. Gore & Associates, INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.